Loss of
body mass linked
to development of Alzheimer’s disease
Loss of body mass over time appears to be strongly linked to
older adults’ risk of developing Alzheimer’s disease (AD), and the
greater the loss the greater the chance of a person developing the
disease, new research has found. The findings are the first to
associate decline in body mass index (BMI) with the eventual onset
of AD. The researchers suggest that the loss of body mass reflects
disease processes and that change in BMI might be a clinical
predictor of the development of AD.
The research, reported in the September 27, 2005, issue of
Neurology, was
conducted by Aron S. Buchman, M.D., David A. Bennett, M.D., and
colleagues at Rush University Medical Center in Chicago, IL, as part
of the Religious Orders Study. The Religious Orders Study is a
comprehensive, long-term look at aging and AD among Catholic nuns,
priests, and brothers nationwide that has been funded by the
National Institute on Aging (NIA), a component of the National
Institutes of Health, U.S. Department of Health and Human Services,
since 1993. Rush University Medical Center is one of more than 30
Alzheimer’s Disease Centers supported by the NIA.
“People with Alzheimer’s disease are known to lose weight and
body mass after they have the disease,” says Dallas W. Anderson,
Ph.D., program director for population studies in the Dementias of
Aging Branch of NIA’s Neuroscience and Neuropsychology of Aging
Program. “This study is significant in that it looks at body mass
changes in the years preceding dementia and cognitive decline. Other
studies have looked at BMI at only one point in time or studied body
mass loss in people who already have AD.”
Each of the 820 study participants took part in yearly
clinical evaluations that included a medical history, neurologic
examination, and extensive cognitive function testing. The
participants’ weights and heights were also measured to determine
their BMI, a widely used measure of body composition that is
calculated by dividing weight in kilograms by height in meters
squared. They completed an average of 6.6 annual evaluations, with a
95 percent follow-up rate. All of the participants were older than
65 years, and the vast majority of them were white and of European
ancestry.
When the study began, none of the participants had dementia,
and their average BMI was 27.4. During the follow-up period, 151 of
the participants (18.4 percent) developed AD. Both baseline BMI and
the annual rate of change in BMI were linked to the risk of
developing AD.
People who lost approximately one unit of BMI per year had a
35 percent greater risk of developing AD than that of people with no
change in BMI over the course of the study. Those with no change in
BMI had a 20 percent greater risk of developing the disease than
that of people who gained six-tenths of a unit of BMI per year.
The findings held true even after adjusting for factors such
as chronic health problems, age, sex, and education. They also held
true when those who developed AD in the first 4 years of follow-up —
and might have had mild, undiagnosed AD early in the study — were
excluded from the analysis.
The investigators found a similar relationship between
changes in BMI and rate of cognitive decline, which is the clinical
hallmark of AD. Even when controlling for baseline cognitive
function, baseline BMI, age, sex, and education, the rate of
cognitive decline among people losing approximately one unit of BMI
per year was more than 35 percent higher than that of people with no
change in BMI and 80 percent higher than that of people who gained
six-tenths of a unit of BMI per year.
Further analyses showed that depressive symptoms,
participants’ physical activity levels, and female participants’ use
of estrogen replacement did not explain the link between BMI loss
and development of AD.
In addition, when the researchers looked at changes in weight
rather than BMI, they found that a loss of 1 pound per year was
associated with a 5 percent increase in the risk of AD.
“These findings suggest that subtle, unexplained body mass
and weight loss in an older person may be an early sign of AD and
can precede the development of obvious memory problems,” explains
Bennett, who directs the Rush Alzheimer’s Disease Center. “The most
likely explanation is that there is something about these
individuals or about this disease that affects BMI before the
clinical syndrome becomes apparent — that loss of BMI reflects the
disease process itself.”
“Our understanding of Alzheimer’s disease is changing as we
get more information, particularly as we look at the pathology of
the disease,” adds Buchman, the lead investigator for the study. “It
turns out that Alzheimer’s disease not only results in cognitive
dysfunction, but also may have a variety of other symptoms,
depending on which brain regions are affected. If the disease
pathology affects a region of the brain that controls weight, your
body mass may decline prior to loss of cognition.”
Based on the Religious Orders Study findings and other
evidence, the researchers suggest that loss of body mass could be
added to the “relatively short list” of signs doctors can use to
predict a person’s risk of developing AD.
“There are actually very few predictors of Alzheimer’s
disease,” Bennett explains. “This study makes us think about the
spectrum of clinical signs of AD beyond changes in memory and
behavior and motor skills. Changes in BMI are easy to measure in a
doctor’s office without an expensive scan,” he says.
Bennett and colleagues acknowledge that the study
participants were limited to Catholic clergy living in communal
settings and recommend replication of the research with more diverse
groups of people. They also note that the group’s homogeneity
strengthened their research because they knew that all of the
participants had access to ample, nutritious food. The authors are
indebted to the altruism and support of the participants in the
Religious Orders Study.
The researchers note that the Religious Orders Study research
complements recently published findings of the Honolulu-Asia Aging
Study, a 32-year population-based study funded jointly by NIA and
the National Heart, Lung, and Blood Institute, NIH. Those findings,
released in the January 2005
Archives of Neurology, show that dementia-associated
weight loss in Japanese-American men begins before the onset of
dementia and accelerates by the time of diagnosis.
For more information on participation in an AD clinical
trial, visit
http://www.clinicaltrials.gov/ (search for "Alzheimer’s disease
trials"), or the Alzheimer’s Disease Education and Referral (ADEAR)
Center website at
http://www.alzheimers.org.
ADEAR may also be contacted toll free at 1-800-438-4380. The
ADEAR Center is sponsored by the NIA to provide information to the
public and health professionals about AD and age-related cognitive
change and may be contacted at the website and phone number above
for a variety of publications and fact sheets, as well as
information on clinical trials.